The Pancreatic Cancer Action Network (PanCAN) is driving research progress by targeting precision medicine and early detection methods for the world’s toughest cancer. The organization, in collaboration with its generous donors, including Tap Cancer Out, has invested $4.9 million in vital pancreatic cancer research through its competitive peer-reviewed 2017 Research Grants Program – awarding 17 grants to 21 researchers at 12 institutions across the country.
“For the first time in the history of our organization, we requested applications focused on high-impact early detection and precision medicine projects leading to new screening and treatment options,” said Julie Fleshman, JD, MBA, president and CEO of the Pancreatic Cancer Action Network. “Additionally, we are continuing to invest in early-career researchers to build the community of those focused on this disease, as well as funding leading-edge translational research that bridges laboratory findings and clinical impact.”
At Tap Cancer Out, we are honored to be one of the named grants: The 2017 Tap Cancer Out – Pancreatic Cancer Action Network Translational Research Grant, which was awarded to Timothy Wang, MD. Dr. Wang is the Silberberg Professor of Medicine, chief of the digestive & liver diseases and director of the gastrointestinal cancer program at Columbia University Medical Center. The Co-principal Investigator is Paul Oberstein, MD, an assistant professor of medicine in the division of hematology/oncology at Columbia University Medical Center. Dr. Wang and Dr. Oberstein’s project is entitled Targeting Cholinergic Receptors to Suppress Pancreatic Cancer and, thanks to Tap Cancer Out and PanCAN, their research will be funded through 2019. Click here to read the full report.
PanCAN’s current grants portfolio is thoughtful and comprehensive, including approaches to unlocking the biology of pancreatic cancer, improving treatments and outcomes for patients and accelerating early detection methods.